https://www.selleckchem.com/btk.html
This study aimed to evaluate the clinical usefulness of the aminotransferase to platelet ratio index (APRI), fibrosis-4 (FIB-4) and modified FIB-4 (m FIB-4) indices in predicting hepatocellular carcinoma (HCC) in patients receiving entecavir (ETV) treatment. Among 1955 patients treated with ETV, a total of 857 treatment-naive CHB patients (liver cirrhosis [LC] 424, non-cirrhosis 433) treated with ETV for 1 year were analyzed. Of the 857 patients, 85 (9.9%) patients (77 in LC group and 8 in non-LC group) developed HCC during the follow-up period.
Like
Comment
Share
